Related Experiment Video
Updated: Aug 9, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Alpha 1-protease inhibitor deficiency. Diagnosis, follow-up and therapy options]
1Klinik für Kardiologie, Angiologie und Pneumologie, Otto-von-Guericke-Universität Magdeburg. Thomas.Koehnlein@medizin.uni-magdeburg.de
Insights
Alpha-1 antitrypsin deficiency, a common genetic disorder, significantly increases the risk of lung emphysema and liver disease in adults. Early diagnosis and treatment, including augmentation therapy, are crucial for managing this condition.
Area of Science:
- Genetics and Medicine
- Pulmonology
- Hepatology
Context:
- Alpha-1 antitrypsin (alpha-1) deficiency is a prevalent hereditary condition, particularly in Caucasians.
- It is a significant underlying cause of chronic obstructive pulmonary disease (COPD) and lung emphysema.
- Affects approximately 2% of COPD and emphysema patients.
Purpose:
- To highlight the clinical significance of alpha-1 antitrypsin deficiency.
- To emphasize the importance of early diagnosis and intervention.
- To outline current diagnostic and therapeutic strategies.
Summary:
- Characterized by reduced levels of alpha-1 antitrypsin, the body's primary antiprotease.
- Presents a high risk for lung emphysema in young adults (30-45 years), with symptoms including cough, sputum, and respiratory insufficiency.
- A moderate risk of liver disease is also associated with this deficiency.
Impact:
- Early detection through serum level measurement is vital for preventing pulmonary function decline.
- Management includes physiotherapy, medications, and antibiotics.
- Intravenous augmentation therapy with purified alpha-1 antitrypsin offers a direct treatment approach.
Definition:
Alpha-1 antitrypsin (alpha-1 proteinase inhibitor) deficiency is characterized by a marked reduction of alpha-1 antitrypsin, the major antiprotease in man.
Prevalence:
Alpha-1 antitrypsin deficiency is one of the most common hereditary diseases in Caucasians of European descent. Alpha-1 antitrypsin deficiency is the underlying disorder in approximately 2% of all patients with chronic obstructive pulmonary disease and lung emphysema.
Clinical Manifestations:
Young adults by the age of 30 to 45 years have a high risk for the development of lung emphysema with cough, sputum expectoration and respiratory insufficiency. There is a moderate risk of liver disease.
Diagnostic Procedures And Treatment:
The diagnosis is obtained by measurement of alpha-1 antitrypsin serum levels. Recognition of the disorder is important to prevent deterioration of the pulmonary function by early initiation of preventive measures and treatment. Therapeutic options are physiotherapy, antiobstructive medication and antibiotics. The most direct approach is the intravenous augmentation therapy with purified alpha-1 antitrypsin.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Alzheimer's Disease: Treatment
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease III: Interprofessional Care

